Edition:
India

Orchard Therapeutics PLC (ORTX.OQ)

ORTX.OQ on NASDAQ Stock Exchange Global Select Market

10.51USD
19 Nov 2019
Change (% chg)

-- (--)
Prev Close
$10.51
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
39,510
52-wk High
$21.50
52-wk Low
$8.65

Latest Key Developments (Source: Significant Developments)

Orchard Therapeutics Announces Launch Of Proposed Public Offering Of 9 Million ADSS Representing 9 Million Ordinary Shares
Tuesday, 4 Jun 2019 

June 3 (Reuters) - Orchard Therapeutics PLC ::ORCHARD THERAPEUTICS PLC SAYS ANNOUNCES LAUNCH OF PROPOSED PUBLIC OFFERING OF 9.0 MILLION ADSS REPRESENTING 9.0 MILLION ORDINARY SHARES.  Full Article

Orchard Therapeutics, Fondazione Telethon And Ospedale San Raffaele Announce Exclusive Worldwide License Agreement For Treatment Of MPS-I
Tuesday, 28 May 2019 

May 28 (Reuters) - Orchard Therapeutics PLC ::ORCHARD THERAPEUTICS, FONDAZIONE TELETHON AND OSPEDALE SAN RAFFAELE ANNOUNCE EXCLUSIVE WORLDWIDE LICENSE AGREEMENT FOR THE TREATMENT OF MPS-I.ORCHARD THERAPEUTICS PLC - TERMS OF DEAL INCLUDE AN UPFRONT PAYMENT IN CASH AS WELL AS CONTINGENT PAYMENTS.ORCHARD THERAPEUTICS - DEAL INCLUDES UPFRONT PAYMENT IN CASH & CONTINGENT PAYMENTS ON ACHIEVEMENT OF FUTURE DEVELOPMENT, REGULATORY, SALES MILESTONES.ORCHARD THERAPEUTICS - TRIAL IS EXPECTED TO ENROLL UP TO EIGHT PATIENTS BY FIRST HALF OF 2020, WITH PRELIMINARY FINDINGS AFTER ONE YEAR OF FOLLOW-UP..ORCHARD THERAPEUTICS - TERMS OF DEAL ALSO INCLUDE ROYALTY PAYMENTS ON NET SALES.  Full Article

Orchard Therapeutics Announces Presentation Of Clinical Proof-Of-Concept For Otl-300
Monday, 15 Apr 2019 

April 15 (Reuters) - Orchard Therapeutics PLC ::ORCHARD THERAPEUTICS ANNOUNCES PRESENTATION OF CLINICAL PROOF-OF-CONCEPT FOR OTL-300 FOR THE TREATMENT OF TRANSFUSION-DEPENDENT BETA-THALASSEMIA AT THE 22ND AMERICAN SOCIETY OF GENE & CELL THERAPY ANNUAL MEETING.ORCHARD THERAPEUTICS PLC - PRIMARY ENDPOINT OF TRANSFUSION REDUCTION WAS ACHIEVED AFTER ONE YEAR OF FOLLOW-UP IN EIGHT OUT OF NINE TDT PATIENTS.ORCHARD THERAPEUTICS PLC - PATIENTS MET SAFETY ENDPOINTS WITH NO ADVERSE EVENTS RELATED TO THERAPY..  Full Article

Orchard Therapeutics And Sirion Biotech Announce Licensing Agreement
Friday, 14 Dec 2018 

Dec 14 (Reuters) - Orchard Therapeutics PLC ::ORCHARD THERAPEUTICS AND SIRION BIOTECH ANNOUNCE LICENSING AGREEMENT TO ENHANCE GENE THERAPY MANUFACTURING EFFICIENCY.ORCHARD THERAPEUTICS PLC - SIRION WILL BE ENTITLED TO UPFRONT AND MILESTONE PAYMENTS.ORCHARD THERAPEUTICS PLC - SIRION IS ELIGIBLE TO RECEIVE ROYALTIES ON NET SALES OF FUTURE PRODUCTS THAT UTILIZE LENTIBOOST TECHNOLOGY..ORCHARD THERAPEUTICS - UNDER TERMS OF AGREEMENT, SIRION WILL PROVIDE CO WITH LICENSE TO ITS PROPRIETARY LENTIVIRAL TRANSDUCTION ENHANCER LENTIBOOST.  Full Article

Orchard Therapeutics Announces The Build-Out Of New Gene Therapy Manufacturing Facility In California
Thursday, 13 Dec 2018 

Dec 13 (Reuters) - Orchard Therapeutics PLC ::ORCHARD THERAPEUTICS ANNOUNCES THE BUILD-OUT OF NEW GENE THERAPY MANUFACTURING FACILITY IN CALIFORNIA.ORCHARD THERAPEUTICS - SIGNED A LONG-TERM LEASE AGREEMENT TO BUILD-OUT A GENE THERAPY MANUFACTURING FACILITY IN FREMONT, CALIFORNIA.  Full Article

Orchard Therapeutics ADS Open 21.4 Pct Above IPO Price In Debut
Wednesday, 31 Oct 2018 

Oct 31 (Reuters) - :ORCHARD THERAPEUTICS ADS DEBUT ON NASDAQ AT $17 VERSUS IPO PRICE OF $14/ADS.  Full Article

Orchard Therapeutics Says Pricing Of Initial Public Offering
Wednesday, 31 Oct 2018 

Oct 30 (Reuters) - Orchard Therapeutics ::ORCHARD THERAPEUTICS ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING.ANNOUNCED PRICING OF ITS INITIAL PUBLIC OFFERING IN UNITED STATES OF 14.29 MILLION AMERICAN DEPOSITARY SHARES ("ADSS") AT PRICE OF $14.00 PER ADS.  Full Article